Put companies on watchlist
PharmaSGP Holding SE
ISIN: DE000A2P4LJ5
WKN: A2P4LJ
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

PharmaSGP Holding SE · ISIN: DE000A2P4LJ5 · EQS - Company News (55 News)
Country: Germany · Primary market: Germany · EQS NID: 1230068
31 August 2021 05:43PM

PharmaSGP Group completes acquisition of OTC brand portfolio (Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R)) from GSK


DGAP-News: PharmaSGP Holding SE / Key word(s): Mergers & Acquisitions
PharmaSGP Group completes acquisition of OTC brand portfolio (Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R)) from GSK

31.08.2021 / 17:43
The issuer is solely responsible for the content of this announcement.


PharmaSGP Group completes acquisition of OTC brand portfolio (Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R)) from GSK

Gräfelfing, August 31, 2021 - PharmaSGP Holding SE announces the formal completion of the purchase agreement signed mid of June with GlaxoSmithKline Group on the acquisition of an OTC portfolio comprising the brands Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R).

The completion of the purchase strategically strengthens PharmaSGP's operations by further expanding the category "Health Brands", enlarging the scope of indications and tapping new markets. Natalie Weigand, CEO of PharmaSGP, was very satisfied with the transaction: "The acquisition and integration of established brands with potential for value growth is a key component of our growth strategy. Baldriparan(R) has been established on the market for 67 years and is the leading OTC brand for natural valerian sleeping aids sold in pharmacies in Germany. We are thus opening up the new indication of sleep disorders. Additionally, Formigran(R), Spalt(R) and Kamol(R) strengthen our strategically important category 'pain therapy'". These four iconic brands with a long tradition in their target markets enjoy a high level of trust and loyalty with consumers, physicians and pharmacists. In 2020, the products of the brand portfolio were distributed in eight countries. Thus, the Group will also be active in Switzerland, Hungary, Poland, Czech Republic and Slovakia in future.

Michael Rudolf, CFO of PharmaSGP, considers the transaction as an achievement of a further milestone on the growth path: "With our products in the field of sleeping disorders and pain therapy, we address two of the best-selling and further growing indications in pharmacies. Thanks to our pan-European platform, we will be able to leverage potential for value enhancement. This is going to positively impact the business development in the year 2021 and beyond. We are convinced of this!"

In September, PharmaSGP will publish a consolidated revenues and earnings forecast for the financial year 2021, including the effects of Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R).

CONTACT

cometis AG
Claudius Krause
Phone: +49-611-20585528
Email: ir@pharmasgp.com

 

ABOUT PHARMASGP HOLDING SE

PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with the focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.

The Company's core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX(R) for rheumatic pain and Restaxil(R) for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio is expanded by the brands Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R), thus also strengthening or developing the indications pain and sleep disorder.

In 2020, PharmaSGP generated revenues of EUR 63.2 million at an adjusted EBIT margin of 26.1 %.

In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP's product offering, increase PharmaSGP's European footprint, and accelerate its growth strategy especially by capitalizing on selected M&A opportunities.



31.08.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: PharmaSGP Holding SE
Lochhamer Schlag 21
82166 Gräfelfing
Germany
E-mail: ir@pharmasgp.com
Internet: https://pharmasgp.com
ISIN: DE000A2P4LJ5
WKN: A2P4LJ
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich
EQS News ID: 1230068

 
End of News DGAP News Service

1230068  31.08.2021 

fncls.ssp?fn=show_t_gif&application_id=1230068&application_name=news&site_id=boersengefluester_html
Visual performance / price development - PharmaSGP Holding SE
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.